Rejuvenate Bio Announces Data for Gene Therapy RJB-01 in Mitral Valve Disease at 2023 Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Excerpt from the Press Release:
SAN DIEGO–(BUSINESS WIRE)–Rejuvenate Bio, today announced new data for its gene therapy RJB-01 from a pilot study in canines with myxomatous mitral valve disease (MMVD), at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 16-20, 2023, in Los Angeles, California.
RJB-01, expresses the genes FGF21 and sTGFßR2 with an adeno-associated virus (AAV) delivery system in order to upregulate FGF21 and downregulate TGFß1 for the treatment of heart failure. MMVD is a common heart valve disease in dogs where the heart valve becomes thickened as a dog ages, causing leakage at the valve that eventually leads to heart failure. The purpose of the study is to determine whether RJB-01 can help delay the progression of this disease.
Results were reported from a subset of the company’s pilot study of RJB-01 in Cavalier King Charles Spaniels (CKCS) for MMVD. Of all the dogs afflicted with MMVD, Cavalier King Charles Spaniels have one of the highest breed incidences, with rates approaching 80%.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?